{"classes":[{"categories":[{"measurements":[{"comment":"N/A = not estimable","groupId":"OG000","spread":"NA","value":"3540"},{"comment":"N/A = not estimable","groupId":"OG001","spread":"NA","value":"3250"},{"comment":"N/A = not estimable","groupId":"OG002","spread":"NA","value":"3720"},{"groupId":"OG003","spread":"50.7","value":"1880"},{"groupId":"OG004","spread":"74.4","value":"3470"},{"groupId":"OG005","spread":"218.9","value":"6230"},{"groupId":"OG006","spread":"4.3","value":"1990"},{"groupId":"OG007","spread":"56.5","value":"2340"},{"groupId":"OG008","spread":"164.4","value":"4230"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"3"}],"units":"Participants"}],"description":"Vz/F is the apparent volume of distribution during terminal phase (associated with Lambda\\_z)","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants receiving 50 mg of LDK378","id":"OG000","title":"LDK378 50 mg"},{"description":"Participants receiving 100 mg of LDK378","id":"OG001","title":"LDK378 100 mg"},{"description":"Participants receiving 200 mg of LDK378","id":"OG002","title":"LDK378 200 mg"},{"description":"Participants receiving 300 mg of LDK378","id":"OG003","title":"LDK378 300 mg"},{"description":"Participants receiving 400 mg of LDK378","id":"OG004","title":"LDK378 400 mg"},{"description":"Participants receiving 500 mg of LDK378","id":"OG005","title":"LDK378 500 mg"},{"description":"Participants receiving 600 mg of LDK378","id":"OG006","title":"LDK378 600 mg"},{"description":"Participants receiving 700 mg of LDK378","id":"OG007","title":"LDK378 700 mg"},{"description":"Participants receiving 750 mg of LDK378.","id":"OG008","title":"LDK378 750 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) consisted of all patients (including NSCLC and non-NSCLC) who received at least 1 dose of LDK378 \\& had at least 1 evaluable PK sample","reportingStatus":"POSTED","timeFrame":"PK Run-in dose escalation phase","title":"Secondary Pharmacokinetics (PK) Parameter: Vz/F","type":"SECONDARY","unitOfMeasure":"Litre"}